Medimerz Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 12 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -90.73%
- Profit Growth -280.32%
- Ebitda -224.52%
- Net Worth -6.74%
- Total Assets -9.09%
About Medimerz Pharma
Medimerz Pharma Private Limited (MPPL) is a Private Limited Indian Non-Government Company incorporated in India on 20 July 2012 and has a history of 12 years and seven months. Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Kishan Bhattar, Sushil Bhattar, Shyam Bhattar, and Two other members serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24234TG2012PTC082093
- Company No.
082093
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Jul 2012
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Medimerz Pharma?
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ram Bhattar  | Director | 09-Aug-2012 | Current |
| Kishan Bhattar | Director | 09-Aug-2012 | Current |
| Sushil Bhattar | Director | 09-Aug-2012 | Current |
| Shyam Bhattar | Director | 09-Aug-2012 | Current |
| Pawan Bhattar | Director | 09-Aug-2012 | Current |
Financial Performance of Medimerz Pharma.
Medimerz Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 90.73% decrease. The company also saw a substantial fall in profitability, with a 280.32% decrease in profit. The company's net worth dipped by a decrease of 6.74%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medimerz Pharma?
In 2023, Medimerz Pharma had a promoter holding of 86.30% and a public holding of 13.70%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Haleness Disposable Products LlpPawan Bhattar is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Medimerz Pharma?
Medimerz Pharma has a workforce of 2 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medimerz Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medimerz Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
